| Literature DB >> 33828886 |
Ayse Pelin Yigider1, Okan Ovunc1, Esra Arslan2, Ahmet Volkan Sunter1, Tevfik Fikret Cermik2, Ozgur Yigit1.
Abstract
OBJECTIVE: Malignant otitis externa (MOE) is a serious disease affecting mainly the elderly diabetic patients that may result in mortality. It was aimed to evaluate the relationship between treatment responses and clinical and radiologic parameters among progress of the disease. Secondary aim was to present our clinical outcomes in the treatment of malignant otitis externa.Entities:
Keywords: Otitis externa; malignant; osteomyelitis; otorrhea; outcome prediction; skull-base
Year: 2021 PMID: 33828886 PMCID: PMC8020189 DOI: 10.5222/MMJ.2021.36528
Source DB: PubMed Journal: Medeni Med J ISSN: 2149-4606
Peleg CT severity score.
| Group 1 (n:10) | ||||
|---|---|---|---|---|
| Area | 0 | 1 | 2 | 3 |
| External Ear canal | No involvement (NI) | Mild thickening | Moderate thickening | Passage closed |
| Mastoid Middle ear | NI NI | Mucosal thickening Mucosal thickening | Fluid & air Fluid & air | Almost full Almost full |
| Nasopharynx | NI | Mild asymmetry / eustachian tube is open | Mild asymmetry / eustachian tube is closed | Severe asymmetry |
| Parotid gland | NI | Mild swelling and infiltration | Severe swelling and infiltration | - |
| Temporal bone | NI | Bone destruction | - | - |
| Temporomandibular joint | NI | Enlarged joint space | Bone destruction | - |
| Skull base | NI | Bone destruction | - | - |
Imaging methods used at the time of diagnosis.
| n | % | |
|---|---|---|
| CT | 4 | 15.4 |
| CT+MR | 7 | 26.9 |
| CT+SCINT | 3 | 11.5 |
| MR+CT+SCINT | 12 | 46.2 |
Distribution of comorbidity at the time of diagnosis.
| n | % | |
|---|---|---|
| 1 | 11 | 42.3 |
| 1+2 | 2 | 7.7 |
| 1+2+12 | 1 | 3.8 |
| 1+2+3+10 | 1 | 3.8 |
| 1+2+3+13 | 1 | 3.8 |
| 1+2+3+6+13 | 1 | 3.8 |
| 1+2+8+11 | 1 | 3.8 |
| 1+3 | 3 | 11.5 |
| 1+3+10 | 1 | 3.8 |
| 1+3+10+13 | 1 | 3.8 |
| 1+4 | 1 | 3.8 |
| 1+5 | 1 | 3.8 |
| 9 | 1 | 3.8 |
DM:1, HT:2, IHD:3, HEARING AID: 4 HEMATOLOGICAL MALIGNANCY: 5 THYROIDITIS: 6, HYPERLIPIDEMIA: 7 GLOCOMA: 8 BPH: 9 NEPHROPATHY: 10, AMPUTATION: 11, COPD: 12 CABG: 13
Culture results.
| n | % | |
|---|---|---|
| Pseudomonas aeruginosa | 16 | 61.5 |
| Coagulase Negative Staphylococcus | 2 | 7.7 |
| Candida | 1 | 3.8 |
| Aspergillus spp. | 1 | 3.8 |
| Skin flora | 3 | 11.5 |
| Escherichia coli | 1 | 3.8 |
| GR - bacillus | 1 | 3.8 |
| Pseudomonas aeruginosa + Candida albicans | 1 | 3.8 |
Peleg staging before and after treatment.
Mean PELEG and CARNEY scores of outcome measures.
| OUTCOME | n | CARNEY score | PELEG score |
|---|---|---|---|
| DOC | 2 | 2.5 | 6 |
| DOD | 7 | 2.71 | 5.3 |
| AWD | 4 | 2.5 | 6.3 |
| NED | 12 | 2.5 | 5.2 |
Comparison of laboratory results before and after treatment.
| Before treatment (Mean±SS) | After treatment (Mean±SS) | P value | |
|---|---|---|---|
| ESR (mm/h) | 56.35±30.37 | 42.92±27.90 | 0.018* |
| CRP (mg/L) | 17.79±37.68 | 11.86±42.95 | 0.036* |
| WBC (x106/L) | 10.54±16.31 | 7.17±2.27 | 0.243 |
| N/L | 3.98±2.81 | 4.19±6.44 | 0.101 |
| PLT (x109/L) | 275.65±109.00 | 227.23±78.58 | 0.004* |
| HBA1c (%) | 7.60±2.23 | 7.09±2.12 | 0.073 |
| Glucose (mg/dL) | 177.48±66.58 | 163.54±77.74 | 0.300 |
| Peleg Staging | 5.04±2.94 | 3.25±1.18 | 0.040* |
*= p<0.05 statistically significant.